Value through InnovationSeptember 14 2016

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10
09.09.2016

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease

09.08.2016

New analysis showed dose adjustment of Gilotrif® (afatinib) improved tolerability without an apparent impact on efficacy in patients with EGFR mutation-positive non-small cell lung cancer

09.07.2016

New Long-Term Data Demonstrates Continued Safety and Beneficial Effect of Ofev® (Nintedanib) for Patients with IPF

09.06.2016

Tiotropium RESPIMAT® Improved Lung Function with Safety Comparable to Placebo in Children with Asthma

09.05.2016

Simple Blood Test Combined with Exacerbation History May Help to Identify When to Add ICS to COPD Treatment

09.05.2016

New Data: STIOLTO® RESPIMAT® (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD

09.01.2016

Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE® immuno-oncology drug for multiple myeloma

08.30.2016

Qualcomm and Boehringer Ingelheim Pharmaceuticals collaborate to add new digital technology to RESPIMAT® inhaler

08.29.2016

ESC Congress 2016 Late Breaking Science Registry: Latest Data on Pradaxa (dabigatran etexilate mesylate) Safety and Effectiveness Profile Show Low Rates of Bleeding and Stroke in NVAF Patients in Routine Clinical Care

08.25.2016

Boehringer Ingelheim and Duke Clinical Research Institute Expand Collaboration to Create Largest Patient Registry for Idiopathic Pulmonary Fibrosis (IPF)

back 1 2 3 4 5 6 7 8 9 10